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Purpose: Complicated urinary tract infections (cUTIs) are among the most frequent health-
care-associated infections. In patients with cUTI, Pseudomonas aeruginosa deserves special 
attention, since it can affect patients with serious underlying conditions. Our aim was to gain 
insight into the risk factors and prognosis of P. aeruginosa cUTIs in a scenario of increasing 
multidrug resistance (MDR).
Methods: This was a multinational, retrospective, observational study at 20 hospitals in south 
and southeastern Europe, Turkey, and Israel including consecutive patients with cUTI hospital-
ized between January 2013 and December 2014. A mixed-effect logistic regression model was 
performed to assess risk factors for P. aeruginosa and MDR P. aeruginosa cUTI.
Results: Of 1,007 episodes of cUTI, 97 (9.6%) were due to P. aeruginosa. Resistance rates of 
P. aeruginosa were: antipseudomonal cephalosporins 35 of 97 (36.1%), aminoglycosides 30 
of 97 (30.9%), piperacillin–tazobactam 21 of 97 (21.6%), fluoroquinolones 43 of 97 (44.3%), 
and carbapenems 28 of 97 (28.8%). The MDR rate was 28 of 97 (28.8%). Independent risk 
factors for P. aeruginosa cUTI were male sex (OR 2.61, 95% CI 1.60–4.27), steroid therapy 
(OR 2.40, 95% CI 1.10–5.27), bedridden functional status (OR 1.79, 95% CI 0.99–3.25), anti-
biotic treatment within the previous 30 days (OR 2.34, 95% CI 1.38–3.94), indwelling urinary 
catheter (OR 2.41, 95% CI 1.43–4.08), and procedures that anatomically modified the urinary 
tract (OR 2.01, 95% CI 1.04–3.87). Independent risk factors for MDR P. aeruginosa cUTI were 
age (OR 0.96, 95% CI 0.93–0.99) and anatomical urinary tract modification (OR 4.75, 95% CI 
1.06–21.26). Readmission was higher in P. aeruginosa cUTI patients than in other etiologies 
(23 of 97 [23.7%] vs 144 of 910 [15.8%], P=0.04), while 30-day mortality was not significantly 
different (seven of 97 [7.2%] vs 77 of 910 [8.5%], P=0.6).
Conclusion: Patients with P. aeruginosa cUTI had characteristically a serious baseline condi-
tion and manipulation of the urinary tract, although their mortality was not higher than that of 
patients with cUTI caused by other etiologies.
Keywords: health care-associated infections, complicated urinary tract infections, Pseudomonas 
aeruginosa, multidrug-resistance
Introduction
Urinary tract infections (UTIs) are among the most frequent infections in both the 
outpatient and inpatient setting. In the last European point-prevalence survey of 
health care-associated infections in acute-care hospitals from 2011 to 2012, UTIs 
were estimated to be the third-most common infection after surgical site infections 
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and pneumonia, accounting for 19% of cases.1 Despite the 
application of specific prevention programs, rates seem to 
be increasing. In the US, 93,300 UTIs occurred in hospi-
talized patients in a 1-year period.2 Given the significant 
incidence of UTI, the impact of the disease on antibiotic 
consumption is noteworthy.3
Complicated UTIs (cUTIs), those occurring in immu-
nocompromised patients or in patients with structural or 
functional urinary tract (UT) abnormalities, have been 
associated with high rates of treatment failure and serious 
complications, especially relapse and development of antibi-
otic resistance.4 These patients constitute a reservoir for the 
spread of multidrug-resistant (MDR) bacteria.
Other issues to consider are the growth of the elderly 
population and the increasing complexity of procedures 
and treatments in patients with cUTI, which entail severe 
immunosuppression and the insertion of foreign bodies and 
devices. In this situation, Gram-negative bacteria with high 
intrinsic resistance, particularly Pseudomonas aeruginosa, 
take on greater relevance.5,6 These microorganisms are associ-
ated with worse prognosis.7 MDR strains of P. aeruginosa, 
such as ST175 or ST111, have spread worldwide. They now 
pose a major challenge for clinicians, since few secondary 
treatment options remain active, and those available have 
side effects.8,9
Given the importance of cUTI in terms of prevalence 
and complexity of disease and the significant pathogenic 
role of P. aeruginosa in this context, it might be of interest 
to identify patients with cUTI who are at risk of infection 
by P. aeruginosa. This can help in the selection of empirical 
treatment in patients with a severe infection. The aim of this 
study was to gain insight into the risk factors for developing 
cUTI caused by P. aeruginosa and MDR P. aeruginosa among 




The COMBACTE-MAGNET WP5 RESCUING study was 
an international, multicenter, retrospective, observational 
cohort study involving hospitalized patients with cUTI 
between January 1, 2013, and December 31, 2014.10,11 This 
study conformed with the STROBE guidelines for reporting 
observational studies.12
Setting and patients
The study was conducted at 20 hospitals in Bulgaria, Greece, 
Hungary, Israel, Italy, Romania, Spain, and Turkey. At each 
hospital, all consecutive patients with a diagnosis of cUTI 
as the primary cause of hospitalization and patients hospital-
ized for another reason but who developed cUTI during their 
hospitalization were eligible for enrollment. The selection 
was done by searching the appropriate ICD-9 CM or ICD-10 
CM codes at discharge (detailed in Supplementary materi-
als), and 50–60 patients were included at each hospital until 
reaching the total estimated sample size of 1,000 patients.13,14
Inclusion criteria, based on the US Food and Drug Admin-
istration (FDA) guidance on cUTI,15 were patients with UTI 
and at least one of:
•	 indwelling urinary catheter, urinary retention (at least 100 
mL of residual urine after voiding), neurogenic bladder, 
obstructive uropathy (eg, nephrolithiasis, fibrosis), renal 
impairment caused by intrinsic renal disease (estimated 
glomerular filtration rate <60 mL/min), renal transplanta-
tion, UT modifications, such as an ileal loop or pouch, 
and pyelonephritis and normal UT anatomy;
•	 at least one of the following signs or symptoms: chills 
or rigors associated with fever or hypothermia (tem-
perature >38°C or <36°C), flank pain (pyelonephritis) 
or pelvic pain, dysuria, urinary frequency, or urinary 
urgency, and costovertebral angle tenderness on physical 
examination;
•	 urine culture with at least 105 colony-forming units/mL or 
greater of an uropathogen (no more than two species), or 
at least one blood culture growing possible uropathogens 
(no more than two species) with no other evident site of 
infection.
Exclusion criteria were age under 18 years, diagnosis of 
prostatitis according to FDA guidance, polymicrobial infec-
tions that included Candida spp., polymicrobial infections 
that included more than two bacterial species, and cUTI with 
Candida spp. as sole uropathogen.
Data collection
Data from eligible patients were collected from January 
2015 until August 2016. For all patients, a standardized set 
of information was collected retrospectively from their elec-
tronic records and the hospital administration and laboratory 
systems. Data included patients’ demographic characteristics, 
comorbidities, place of acquisition of infection, signs and 
symptoms of infection, laboratory and microbiology tests, 
details of discharge, and outcome of infection, including death 
if applicable. The follow-up period was up to 2 months after 
hospital discharge. Patients without visits after discharge and 
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Complicated P. aeruginosa urinary tract infections
for outcome purposes. For data collection, a controlled-access 
web-based electronic case report form was used. For confirma-
tion of data quality, study sites were monitored and audited.
Definitions
Acquisition of cUTI in a medical care facility was considered 
if it was:
•	 hospital-acquired: if it started 48 hours or more after 
hospital admission;
•	 health care-associated: if it was detected at hospital 
admission or within the first 48 hours of hospitalization 
and met any of the following criteria: 1) receiving intra-
venous therapy, wound care, or specialized nursing care 
at home in the previous 30 days, 2) attendance at hospital 
or hemodialysis ward or administration of intravenous 
chemotherapy in the previous 30 days, 3) hospitalization 
for 2 or more days in the previous 90 days, 4) residence 
in a long-term care facility, 5) invasive urinary procedure 
performed in the previous 30 days, or 6) a long-term 
indwelling urethral catheter.
The following cUTI categories were used:
•	 UTI related to indwelling urinary catheterization, includ-
ing long-term, short-term, or intermittent catheterization
•	 pyelonephritis, defined as sepsis, flank pain, or tenderness, 
and no other UT pathology.
•	 UTI related to anatomical UT modification, including 
any urinary diversion procedure, nephrostomy, stents, or 
renal transplants.
•	 UTI related to obstructive uropathy, including any 
obstruction intrinsic or extrinsic to the UT, such as lithia-
sis, tumor, ureteral herniation, and prostate hyperplasia
•	 UTI related to other events that did not fall under any 
other category, such as neurogenic bladder.
MDR P. aeruginosa was defined in accordance with 
the international expert proposal published by Magiorakos 
et al: insusceptibility to at least one agent in three or more 
antimicrobial categories (aminoglycosides, antipseudomonal 
carbapenems, antipseudomonal cephalosporins, antipseu-
domonal fluoroquinolones, antipseudomonal penicillins + 
β-lactamase inhibitors, monobactams, phosphonic acids, 
and polymyxins).16 Extensive drug resistance was defined as 
insusceptibility to at least one agent in all but two or fewer 
antimicrobial categories. Clinical and Laboratory Standards 
Institute or European Committee on Antimicrobial Suscep-
tibility Testing guidelines were followed depending on each 
hospital protocol.
Steroid therapy was considered as the administration of 
a dose of ≥10 mg prednisolone or equivalent for 30 days or 
more prior to the diagnosis of cUTI. P. aeruginosa cUTI was 
defined as isolation of P. aeruginosa in urine cultures and/or 
blood cultures in accordance with the aforementioned inclu-
sion and exclusion criteria. Adequate empirical antibiotic 
treatment was considered the empirical administration of 
at least one antimicrobial agent to which the P. aeruginosa 
isolate was susceptible according to microbiological sensi-
tivity tests.
Primary outcome
The primary outcome was the analysis of independent predic-
tive factors of P. aeruginosa cUTI and MDR P. aeruginosa 
cUTI. Secondary outcomes included comparison of evolu-
tion of P. aeruginosa cUTI and cUTI by other etiologies and 
evaluation of differences in mortality between cUTI caused 
by P. aeruginosa and MDR P. aeruginosa.
Statistical methods
Nominal categorical variables are presented as number of 
cases and percentage of the total. Ordinal categorical vari-
ables and continuous variables that did not follow a normal 
distribution are described as medians and interquartile ranges. 
Continuous variables with normal distribution are described 
as mean and SD. Normality of continuous variables was 
graphically tested through Q–Q plots and histograms. The χ2 
or Fisher’s exact tests were used to compare categorical data 
and Student’s t-test or Mann–Whitney U test for continuous 
data, as appropriate.
After univariate analyses, a mixed-effect logistic regres-
sion multivariate analysis was estimated to assess association 
between P. aeruginosa cUTI and patient profiles, accounting 
for center effect. A mixed-effect logistic regression multi-
variate analysis was estimated to assess association between 
MDR P. aeruginosa cUTI and patient profile, accounting 
for country effect. Country instead of center was used as 
a cluster in the MDR P. aeruginosa model, due to the low 
number of events per center. Collinearity between variables 
was evaluated. Selection of model variables was based on 
minimization of the Akaike information criterion. The effect 
of center was assessed using intraclass correlations, which 
measured the proportion of total variance of the dependent 
variable explained by center or country effect. The higher the 
value, the more center or country effect. Results are given as 
ORs and 95% CIs. All tests were two-tailed, and P<0.05 was 
considered statistically significant. Data were managed and 
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Ethics approval and informed 
consent
This study was approved by the Comitato Etico Provinciale 
di Modena and thereafter the local research ethics committee 
of each site. The processing of patients’ personal data was 
anonymized and complied with local data-protection legisla-
tions and with the European Union Data Protection Directive 
(95/46/EC). The study was conducted in accordance with 
the Declaration of Helsinki. As neither individual data were 
published nor any intervention was performed on patients, 
patient consent was waived by the ethics committee.
Results
Epidemiological characteristics of cUTI 
episodes
A total of 1,007 cUTI episodes from 981 patients were 
included. Differences between episodes of P. aeruginosa 
cUTI and episodes of cUTI caused by other etiologies are 
shown in Table 1. Differences between MDR P. aeruginosa 
cUTI and non-MDR P. aeruginosa cUTI episodes are shown 
in Supplementary materials.
Microbiological features of P. aeruginosa 
cUTI and cUTI due to other etiologies
Of all episodes, 97 were P. aeruginosa. Among these, 15 
episodes (15.4%) had P. aeruginosa-positive blood cultures. 
Compared to other etiologies, P. aeruginosa cUTIs were more 
frequently polymicrobial (39.2% vs 9.7%, P<0.001). Associ-
ated microorganisms were mostly Enterococcus spp. (Table 2).
Antibiotic-resistance profile of P. 
aeruginosa isolates
The resistance profile of the 97 P. aeruginosa isolates is shown 
in Table 3. Resistance rates to antipseudomonal cephalosporins 
were 35 of 97 (36.1%), to aminoglycosides 30 of 97 (30.9%), 
to piperacillin–tazobactam 21 of 97 (21.6%), to fluoroquino-
lones 43 of 97 (44.3%), and to carbapenems 28 of 97 (28.8%). 
The rate of MDR P. aeruginosa was 28 of 97 (28.8%) and of 
extensively drug-resistant P. aeruginosa 12 of 97 (12.3%).
Table 1 Epidemiological characteristics and outcomes of episodes of Pseudomonas aeruginosa cUTI and cUTI due to other etiologies




OR (95% CI) ICC
Male sex, n (%) 69 (71.1) 393 (44.2) 3.29 (2.06–5.25) 0.072
Age (years), mean, SD 66.1, 18.1 65.9, 17.9 1.00 (0.99–1.01) 0.072
Diabetes mellitus, n (%) 27 (27.8) 239 (26.3) 1.11 (0.69–1.79) 0.072
Lymphoma, n (%) 2 (2.1) 11 (1.2) 1.76 (0.38–8.21) 0.072
Solid tumor, n (%) 18 (18.6) 102 (11.2) 1.83 (1.04–3.21) 0.072
Liver disease, n (%) 6 (6.2) 47 (5.2) 1.39 (0.56–3.43) 0.074
Admission: urgent, n (%) 83 (85.6) 722 (84.8) 0.92 (0.48–1.74) 0.074
Admission reason: UTI, n (%) 45 (46.4) 606 (66.6) 0.46 (0.29–0.73) 0.038
Admission from medical care facility, n (%) 21 (21.6) 157 (17.3) 1.32 (0.79–2.21) 0.080
Charlson score, mean, SD 3.18, 2.46 2.65, 2.51 1.09 (1.00–1.18) 0.074
Organ transplantation, n (%) 9 (9.3) 60 (6.6) 1.85 (0.84–4.08) 0.082
Immunosuppression, n (%) 11 (11.3) 88 (9.7) 1.43 (0.71–2.86) 0.078
Steroid therapy, n (%) 13 (13.4) 56 (6.2) 2.97 (1.46–6.05) 0.087
Functional capacity: independent (%) 44 (45.4) 492 (54.2) 0.42 (0.23–0.75) 0.087
Chronic renal impairment, n (%) 18 (18.6) 236 (26) 0.66 (0.37–1.15) 0.068
UTI within 1 year, n (%) 29 (29.9) 234 (25.7) 1.38 (0.85–2.24) 0.080
Antibiotic within 30 days, n (%) 32 (33) 171 (18.9) 2.30 (1.44–3.68) 0.072
Acquisition of cUTI at a medical care facility, n (%) 61 (62.9) 390 (42.9) 2.17 (1.38–3.41) 0.055
Urinary retention, n (%) 24 (24.7) 179 (19.7) 1.22 (0.72–2.10) 0.067
Neurogenic bladder 3 (3.1) 44 (4.8) 0.64 (0.20–2.12) 0.077
Obstructive uropathy 20 (20.6) 197 (21.7) 0.96 (0.56–1.65) 0.071
Source of cUTI, n (%) 0.038
Indwelling urinary catheter 57 (58.8) 284 (31.2) 2.75 (1.73–4.35)
Pyelonephritis (normal urinary tract) 4 (4.1) 196 (21.5) 0.17 (0.05–0.55)
Others 36 (37.1) 430 (47.3) 0.58 (0.24–1.40)
Severity of infection: severe sepsis/septic shock, n (%) 18 (20.2) 131 (15.4) 1.30 (0.66–2.56) 0.083
Adequate empiric antibiotic treatment, n (%) 33/81 (40.7) 483/759 (63.6) 0.39 (0.24–0.62)
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Complicated P. aeruginosa urinary tract infections
Rates and risk factors for P. aeruginosa 
cUTI and MDR P. aeruginosa cUTI
By mixed-effects logistic regression model accounting 
for center effect, male sex (OR 2.61, 95% CI 1.60–4.27), 
steroid therapy (OR 2.40, 95% CI 1.10–5.27), a bedridden 
functional capacity (OR 1.79, 95% CI 0.99–3.25), antibiotic 
treatment within 30 previous days of cUTI (OR 2.34, 95% 
CI 1.38–3.94), indwelling urinary catheter (OR 2.41, 95% 
CI 1.43–4.08), and anatomical UT modification (OR 2.01, 
95% CI 1.04–3.87) as sources of infection were identified as 
independent risk factors for P. aeruginosa cUTI (Table 4). 
Figure 1 shows the differences in P. aeruginosa cUTI preva-
lence in the different participating centers.
Factors independently associated with MDR P. aerugi-
nosa cUTI compared to cUTI caused by non-MDR P. aeru-
ginosa, accounting for country effect, were age (OR 0.96, 
95% CI 0.93–0.99) and modification of the UT as source of 
cUTI (OR 4.75, 95% CI 1.06–21.26), as shown in Table 5. 
Figure 2 shows the prevalence of MDR P. aeruginosa cUTI 
in the eight participating countries.
Outcomes
For readmission and mortality, a slightly higher 60-day 
readmission rate was found in P. aeruginosa cUTI com-
pared to other etiologies (23/97 vs 144/910, P=0.04; Table 
6). Thirty-day mortality did not significantly differ between 
cUTI caused by P. aeruginosa or by other etiologies; however, 
there were differences in mortality between non-MDR P. 
aeruginosa cUTI (six of 60, 10%) and MDR P. aeruginosa 
cUTI (one of 37, 2.7%), but they did not reach statistical 
significance (P=0.17; results not shown).
Discussion
In this international, multicenter, retrospective, obser-
vational study, we found that factors associated with P. 
aeruginosa were male sex, steroid therapy, low functional 
capacity, having had antibiotics and manipulation of the 
cUTI, either insertion of urinary catheter or surgical 
procedures that anatomically modify the UT. Of these, 
anatomical UT modification was a risk factor for MDR 
P. aeruginosa cUTI, as was, unexpectedly, young age. 
Interestingly, although hospital readmission was higher in 
patients with P.  aeruginosa cUTI, mortality was not higher 
than other etiologies.
Table 2 Microbiological features of cUTI episodes with or without Pseudomonas aeruginosa





Polymicrobial infection,a n (%) 38 (39.2) 88 (9.7) <0.001
Escherichia coli 8 (8.2) 557 (61.2) <0.001
Klebsiella pneumoniae 7 (7.2) 161 (17.7) 0.009
Proteus mirabilis 1 (1) 78 (8.6) 0.009
Enterococcus spp. 14 (14.4) 55 (6) 0.002
Note: aComprised no more than two bacterial species.
Abbreviation: cUTI, complicated urinary tract infection.
Table 3 Antibiotic-resistance profile of Pseudomonas aeruginosa 
complicated urinary tractinfection episodes (n=97)
Antibiotics Resistance (n) (%)





Multidrug resistance 28 28.8
Extensive drug resistance 12 12.3
Table 4 Predictive factors of Pseudomonas aeruginosa complicated 
urinary tractinfection episodes: mixed-effect logistic regression 
model
OR 95% CI P-value
Intercept 0.03 0.01 0.08 <0.001
Sex: male 2.61 1.60 4.27 <0.001
Agea 1.00 0.98 1.01 0.584
Active chemotherapy 1.99 0.67 5.91 0.214
Corticosteroid therapy 2.40 1.10 5.27 0.029
Functional capacity: 
bedridden
1.79 0.99 3.25 0.056
Antibiotic within 30 
days
2.34 1.38 3.94 0.002
Indwelling urinary 
catheter
2.41 1.43 4.08 0.001
Anatomical urinary 
tract modification
2.01 1.04 3.87 0.038
Notes: Random part: center variance 0.417, intraclass correlation 0.113. Other 
information: observations 1,007, Akaike information criterion 583.742. aOR values 
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In our cohort, P. aeruginosa cUTIs were more frequently 
polymicrobial than cUTIs caused by other microorganisms. 
Interestingly, associated microorganisms in P. aeruginosa 
cUTI were more frequently Gram-positive, especially Entero-
coccus spp., than Gram-negative. The same association has 
been observed in other studies, and could be explained by 
an enhanced ability to adhere to urinary catheters through 
different factors and biofilm formation of Enterococcus spp. 
and P. aeruginosa.3,17–20
In regard to the antimicrobial resistance of P. aeru-
ginosa isolates, high resistance to fluoroquinolones was 
documented, as previously observed in the European 
Antimicrobial Resistance Surveillance Network report.21 
Significantly, 36% of P. aeruginosa strains were resistant 
to antipseudomonal cephalosporins. This tendency was 
also observed in a recent Turkish study among hospitalized 
men with P. aeruginosa cUTI.22 Piperacillin–tazobactam 
maintained a better resistance profile than antipseudo-
monal cephalosporins, maybe because it is less affected by 
certain AmpC β-lactamase variants and extended spectrum 
β-lactamases.23,24 Notably, 28.8% of P. aeruginosa isolates 
were resistant to carbapenems, a rate significantly higher 
than previously reported.22,25 In our study, the MDR rate 
of P. aeruginosa was 28.8%, slightly higher than in previ-
ous work; however, considering that our study focused on 
countries with a high incidence of MDR Gram-negative 
bacteria and that some of the studies mentioned were 
performed some years ago, this increase was expected.18,26
Importantly, rates of P. aeruginosa cUTI varied sig-
nificantly among hospitals in the same country and among 
countries. This reflects the wide heterogeneity of patients 
and procedures performed in each hospital. Some of the 
risk factors observed in the present study, such as receiving 
corticosteroids or antibiotics, have been described by other 
authors, and reflect the opportunistic and nosocomial nature 
of infections due to P. aeruginosa.27,28 Previous exposure 
to antibiotics may be related to the effect of eradication of 
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Figure 1 Prevalence with 95% CIs of Pseudomonas aeruginosa complicated urinary tract-infection episodes by centers (A–R) and countries.
Table 5 Predictive factors of multidrug-resistant Pseudomonas 
aeruginosa: mixed-effect logistic regression model
OR 95% CI P-value
Intercept 5.07 0.55–46.64 0.151
Male sex 0.73 0.23–2.35 0.602




Obstructive uropathyb 2.83 0.67–11–85 0.155
Other source eventsb 0.24 0.04–1.45 0.121
Notes: Random parts: country variance 0.097, intraclass correlation 0.029. Other 
information: observations 97, Akaike information criterion 113.678. aOR values 
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Complicated P. aeruginosa urinary tract infections
ments.29 The indication of steroids and antibiotics should be 
carefully evaluated in every patient, given the high risk of P. 
aeruginosa infections.
As mentioned, P. aeruginosa can adhere to such sur-
faces as urinary catheters or foreign bodies inserted during 
urological surgery through production of adhesion factors 
and biofilm formation. This allows the microorganism to 
elude the immune system and the activity of antimicrobial 
agents, and persist in causing frequent relapses of infection.19 
Therefore, the indication for insertion of an indwelling 
urinary catheter and its duration should also be periodically 
evaluated.
Interestingly, younger patients were at higher risk of hav-
ing MDR P. aeruginosa cUTI than older patients. This was 
probably related to the fact that young patients are more likely 
to receive aggressive antimicrobial and surgical treatment 
than old patients and more frequently admitted to intensive-
care units when complications arise, increasing the risk of 
acquiring a MDR isolate.30 Procedures that modified the UT 
represented a strong risk factor for MDR P. aeruginosa in 
our cohort.
P. aeruginosa cUTI was associated with a lower rate of 
adequate empirical treatment than cUTI by other etiologies. 
Nevertheless, a previous study in the same cohort showed 
that inadequate empirical antibiotic treatment was not inde-
pendently associated with increased mortality.11 The lack 
of differences observed in mortality between P. aeruginosa 
and other etiologies was probably due to the low frequency 
of severe sepsis or septic shock and mortality in our cohort. 
Although many previous studies have observed worse 
outcomes of UTIs caused by P. aeruginosa, this was more 
frequently related to a more serious baseline status due to 
comorbidities than to the infection itself. For instance, one 
study of bacteremic UTIs showed that P. aeruginosa UTIs 
were associated with higher 30-day mortality than other 
etiologies, but this result did not remain significant after 
adjustment for confounding factors.31 Similar results have 
been observed in other work.18 The readmission rate was 
higher in patients with P. aeruginosa cUTIs, but this was 
mostly due to exacerbation of chronic baseline diseases: this 
observation stresses that these patients had worse baseline 
status. Interestingly, low mortality associated with MDR P. 
Table 6 Outcomes of episodes of Pseudomonas aeruginosa cUTI and episodes of cUTI caused by other etiologies
Risk factors Entire cohort 
(n=1,007), n (%)





Symptom improvement at 5–7 days, n (%) 756 (75) 74 (76.5) 682 (75) 0.7
Symptom recurrence within 30 days, n (%) 81 (8) 11 (11.6) 70 (7.7) 0.2
Mortality at 30 days, n (%) 84 (8.3) 7 (7.2) 77 (8.5) 0.6
Readmission within 60 days after discharge, n (%) 167 (16.5) 23 (23.7) 144 (15.8) 0.04
Readmission due to cUTI, n (%) 81 (8) 10 (10.3) 71 (7.8) 0.4
Abbreviation: cUTI, complicated urinary tract infection.
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aeruginosa cUTI was observed. This was probably due to 
the small number of patients with MDR strains, but also 
because these strains have been associated with reduced 
fitness and virulence.8
Limitations 
Our study has some limitations. The first is its retrospec-
tive design, which means that some patients’ data collected 
from medical records may have been missing. Second, the 
data come from hospitals in south and southeastern Europe, 
Turkey, and Israel, and may not be generalizable to other 
regions. The main strengths of this study are its large-scale, 
multicenter, and international nature and the fact that it 
addresses a frequent and important medical issue.
Conclusion
Our study reveals that resistance rates of P. aeruginosa cUTI 
isolates to antipseudomonal cephalosporins and carbapenems 
are especially worrisome in south and southeastern Europe, 
Turkey, and Israel. Risk factors for P. aeruginosa cUTI were 
related to more serious baseline condition and manipulation 
of the UT, although their mortality was not higher than that 
of patients with cUTI caused by other etiologies.
Abbreviations
UT, urinary tract; UTIs, urinary tract infections; cUTIs, com-
plicated urinary tract infections; MDR, multidrug-resistance; 
GNB, Gram-negative bacteria; STROBE, Strengthening the 
Reporting of Observational studies in Epidemiology; ICD-9 
(-10) CM, International Classification of Diseases-9 (-10) 
Clinical Modification; FDA, Food and Drug Admin-istration; 
CFU, colony-forming units; eCRF, electronic case report 
form; XDR, extensively drug-resistance; CLSI, Clinical 
and Laboratory Standards Institute; EUCAST, European 
Committee on Antimicrobial Susceptibility Testing; IQR, 
interquartile range; SD, standard deviation; ICC, Intra-
class-correlation; OR, odds ratio; 95% CI, 95% confidence 
interval; EARS-Net, European Antimicrobial Resistance 
Surveillance Network.
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Table S1 Univariate analysis of risk factors associated with MDR Pseudomonas aeruginosa cUTI compared to non-MDR P. aeruginosa 
cUTI, accounting for country effect
MDR P. aeruginosa 
cUTI (n=28)
Non-MDR P. aeruginosa 
cUTI (n=69)
OR (95% CI) ICC
Male sex, n (%) 21 (75) 48 (69.5) 1.26 (0.44–3.60) 0.102
Age (years), mean, SD 59.3, 19.12 68.9, 17.06 0.97 (0.95–1.00) 0.072
Lymphoma, n (%) 1 (3.6) 1 (1.4) 4.61 (0.22–94.67) 0.121
Solid tumor, n (%) 4 (14.3) 14 (20.3) 0.77 (0.22–2.74) 0.097
Liver disease, n (%) 3 (10.5) 3 (4.3) 3.58 (0.58–22.03) 0.124
Admission: urgent, n (%) 4 (14.3) 10 (14.5) 0.77 (0.19–3.09) 0.101
Admission reason: UTI, n (%) 52 (53.6) 304 (33.4) 0.67 (0.24–1.84) 0.101
Admission from medical care facility, n (%) 10 (26.3) 168 (17.3) 1.70 (0.81–3.57) 0.071
Charlson score, n (%) 17 (44.7) 293 (30.2) 0.97 (0.79–1.19) 0.097
Organ transplantation, n (%) 2 (7.1) 4 (5.8) 1.94 (0.39–9.69) 0.124
Immunosuppression, n (%) 4 (14.3) 7 (10.1) 2.09 (0.48–9.07) 0.123
Steroid therapy, n (%) 5 (17.9) 8 (11.6) 1.86 (0.51–6.82) 0.113
Functional capacity: independent, n (%) 12 (42.9) 41 (59.4) 1.45 (0.43–4.84) 0.116
Chronic renal impairment, n (%) 6 (21.4) 12 (17.4) 1.50 (0.46–4.86) 0.112
UTI within 1 year, n (%) 9 (32.1) 20 (29) 1.54 (0.51–4.61) 0.121
Antibiotic within 30 days, n (%) 9 (32.1) 23 (33.3) 1.06 (0.39–2.89) 0.105
Acquisition of cUTI at a medical care facility, n (%) 20 (71.4) 41 (59.4) 1.91 (0.67–5.44) 0.118
Urinary retention, n (%) 5 (17.9) 19 (27.5) 0.79 (0.23–2.76) 0.090
Neurogenic bladder 1 (3.6) 2 (2.9) 1.14 (0.08–15.86) 0.112
Obstructive uropathy 5 (17.9) 7 (10.1) 1.14 (0.48–4.40) 0.102
Source of cUTI, n (%) 0.102
Indwelling urinary catheter 15 (53.6) 42 (60.9) 1.03 (0.39–2.73)
Pyelonephritis (normal urinary tract) – – –
Anatomical urinary tract modification 6 (21.4) 4 (5.8) 4.43 (1.14–17.17)
Others 2 (7.1) 12 (17.4) 0.58 (0.24–1.40)
Severity of infection: severe sepsis/septic shock, n (%) 4 (15.4) 14 (22.2) 0.63 (0.18–2.15) 0.083
Abbreviations: MDR, multidrug resistance; cUTI, complicated urinary tract infection; ICC, intra-class-correlation; SD, standard deviation; UTI, urinary tract infection.
Variable definitions
•	 Sepsis was defined as a diagnosis of systemic inflammatory 
response syndrome –SIRS- (at least two of the following: 
temperature > 38.3 or <36, respiratory rate > 20 min or 
paCO2 <32 mmHg (4.3 kPa)) in the presence of an infection.
•	 Severe sepsis was defined as sepsis together with evidence 
of organ dysfunction.
•	 Septic shock was defined as sepsis associated with hypo-
tension (systolic blood pressure <90 mmHg or reduction 
of > 40 mmHg from baseline) or lactic acidosis (lactate 
> 4 mmol/L) despite adequate fluid resuscitation.
•	 Liver disease was defined as chronic liver failure, usually 
occurring in the context of cirrhosis. Mild liver disease 
could be classified as cirrhosis without portal hyperten-
sion, or chronic hepatitis. Moderate or severe liver disease 
as cirrhosis with portal hypertension.
•	 Chronic renal impairment was defined as an eGFR of 
60 ml/min/1.732 (measured by the Cockroft-Gault equa-
tion) or less, or a creatinine of > 2.5mg/dL. Patients with 
renal replacement therapy were included. Patients with 
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Table S2 ICD9 data
ICD-9 CM codes Disease
590.1 Acute pyelonephritis
590.10 Acute pyelonephritis without lesion of renal medullary necrosis
590.11 Acute pyelonephritis with lesion of renal medullary necrosis
590.2 Renal perinephric abscess
590.8 Other pyelonephritis or pyonephrosis not specified as acute or chronic
590.80 Pyelonephritis, unspecified
590.9 Infection of kidney, unspecified
595.0 Acute cystitis
595.89 Other specified types of cystitis
595.9 Cystitis, unspecified
599.0 Urinary tract infection, site not specified (urosepsis could be included here)
Notes: ICD9 CM code database http://icd9data.com/2015/volume1/580-629/default.htm.
Abbreviation: ICD-9 CM, International Classification of Diseases-9 Clinical Modification.
Table S3 ICD data
ICD-10 CM codes Disease
N10 Acute tubulointerstitial nephritis, including acute infectious interstitial 
nephritis, acute pyelitis, and acute pyelonephritis
N12 Tubulointerstitial nephritis, not specified as acute or chronic including 
interstitial nephritis NOS, pyelitis NOS, and pyelonephritis NOS
N13.6 Pyonephrosis, including obstructive uropathy with infection
N15.1 Renal and perinephric abscess
N15.9 Renal tubulointerstitial disease, unspecified including infection of kidney NOS
N30.0 Acute cystitis
N30.8 Other cystitis, including abscess of bladder
N30.9 Cystitis, unspecified
N39.0 Urinary tract infection, site not specified
Notes: ICD10 CM code database http://apps.who.int/classifications/icd10/browse/2015/en.
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